{"id":9497,"date":"2016-03-08T17:25:03","date_gmt":"2016-03-08T16:25:03","guid":{"rendered":"https:\/\/mileon.wordpress.com\/?p=9497"},"modified":"2016-03-08T17:25:03","modified_gmt":"2016-03-08T16:25:03","slug":"sesion-de-residentes-the-lancet","status":"publish","type":"post","link":"https:\/\/www.icscyl.com\/mileon\/residentes\/2016-03-08\/sesion-de-residentes-the-lancet\/","title":{"rendered":"Sesi\u00f3n de residentes: The Lancet."},"content":{"rendered":"<p style=\"text-align:justify;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright  wp-image-9498\" src=\"https:\/\/mileon.files.wordpress.com\/2016\/03\/imagen3.jpg\" alt=\"Imagen\" width=\"97\" height=\"141\" \/>El 7 de marzo de 2016 la Dra. M\u00aa Cruz P\u00e9rez Panizo (R5 MI) coment\u00f3 el art\u00edculo:<\/p>\n<ul style=\"text-align:justify;\">\n<li><em>Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.<\/em><\/li>\n<\/ul>\n<p style=\"text-align:justify;\">La calidad de la evidencia fue alta, aunque dir\u00eda con matices entre otros por la limitaci\u00f3n en la extrapolaci\u00f3n de sus resultados a los enfermos que vemos todos los d\u00edas.\u00a0Su presentaci\u00f3n se puede ver en el siguiente <strong><a href=\"https:\/\/drive.google.com\/file\/d\/0BxXYCqMXR4ZaVmEySlAxdXBNQlU\/view?usp=sharing\">enlace.<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El 7 de marzo de 2016 la Dra. M\u00aa Cruz P\u00e9rez Panizo (R5 MI) coment\u00f3 el art\u00edculo: Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. La calidad de la evidencia fue alta, aunque dir\u00eda con matices entre otros por la limitaci\u00f3n en [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[721],"tags":[],"class_list":["post-9497","post","type-post","status-publish","format-standard","hentry","category-residentes"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/9497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/comments?post=9497"}],"version-history":[{"count":0,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/9497\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/media?parent=9497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/categories?post=9497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/tags?post=9497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}